Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection. Methods for making an immunogenic conjugate comprising Streptococcus pneumoniae serotype 19A polysaccharide are also provided in which the serotype 19A polysaccharide is co-lyophilized with a carrier protein and conjugation is carried out in dimethyl sulfoxide (DMSO) via a reductive amination mechanism.

Abstract: A Pseudomonas monteilii strain with salinity-alkalinity tolerance is provided. The strain is Pseudomonas monteilii 9-2, which has been deposited in China General Microbiological Culture Collection Center (CGMCC) on Oct. 25, 2021, with an accession number of CGMCC No. 23666; and an internal transcribed spacer (ITS) sequence is shown in SEQ ID NO: 1. This application further provides an application of the Pseudomonas monteilii strain in the degradation of petroleum hydrocarbons in a saline-alkali environment.

Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.

Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified predictive target biomarkers associated with predicting the risk of an individual developing IBD and includes one or more predictive panels of prediction target biomarkers that are used to determine the risk of an individual developing IBD for determining if a therapy should be administered to reduce the risk and further determines the efficacy of treating the individual with mesalamine and effectively identifies and validates novel drug targets for new IBD therapeutics, new diagnostics and diagnostics standards for IBD therapeutic strategies.

Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.

Abstract: An object of the present invention is to provide a recombinant phage having high safety and excellent practicality and usefulness. Provided are a recombinant bacteriophage which is deprived of its proliferative capacity and can infect only once due to the fact that a bacteriophage genome in which a part of a virion constituent gene is deleted is stored in a head, and a method for preparing the same. In addition, provided are a recombinant bacteriophage which is deprived of its proliferative capacity and can infect only once due to the fact that a plasmid having a packaging site and encoding a target gene is stored in a head, and a method for preparing the same.

Abstract: A method for treating chronic pancreatitis and diabetes type II in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The subcutaneous or intradermal injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, a sacral nerve, or a combination thereof.

Abstract: An oral vaccine for immunization against ETEC-induced diarrhea, comprising inactivated Escherichia coli cells expressing an ETEC colonization factor antigen and dmLT protein adjuvant, wherein the vaccine preferably comprises less than 1013 cells per unit dose.

Abstract: Methods for preventing, treating or diagnosing Type 1 Diabetes (T1D) are described. Amyloid-producing bacteria within microbiota are inactivated. Amyloid-producing bacteria are inactivated in microbiota, gastrointestinal tract, bodily fluids or tissues. Type-1 Diabetes associated microbial product production or release by microbiota is prevented. Also described is inactivation of bacteria-derived T1DAMP present in microbiota, bodily fluids or tissues of a mammal. Release of bacteria-derived T1DAMP from biofilm or bacteria to gastrointestinal tract is inhibited. Entry of bacteria-derived T1DAMP to microbiota, gastrointestinal tract, bodily fluids or tissues of a mammal is inhibited.

Abstract: The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating epilepsy, epileptic seizures and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.

Abstract: The invention relates to the use of melanin, complexed with an antigen, as a immunostimulatory composition.

Abstract: A method of taking a skin sample can include placing an adhesive onto a portion of skin and lifting the adhesive from the skin. A skin sample may then be tested while still on the adhesive, for example, by inoculating the sample with a bacterium, fungus, virus, or a combination.

Abstract: Provided herein are recombinant fusion polypeptides comprising one or more antigenic peptides (e.g., fused to a PEST-containing peptide) from cancer-associated proteins. The antigenic peptides can comprise one or more or all of an antigenic peptide comprising a recurrent cancer mutation, an antigenic peptide comprising a heteroclitic mutation, or an antigenic peptide fused to a ubiquitin protein. For example, provided herein are recombinant fusion polypeptides comprising two or more antigenic peptides (e.g., fused to a PEST-containing peptide), wherein each antigenic peptide comprises a recurrent cancer mutation, and wherein at least two of the antigenic peptides are fragments of the same cancer-associated protein. Also provided are nucleic acids encoding such fusion polypeptides, recombinant bacteria or Listeria strains comprising such fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or Listeria strains.

Abstract: The present invention relates to vesicles derived from genus Morganella bacteria and a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples derived from patients with a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease as compared to normal persons, and the vesicles suppressed the secretion of inflammatory mediators by pathogenic vesicles and suppressed the occurrence of cancer, so that the vesicles derived from genus Morganella bacteria may be usefully used for the purpose of developing a method for diagnosing a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cance

Abstract: The invention provides propagator cells and methods for propagating phage and transduction particles.

Abstract: Provided are vesicles derived from bacteria belonging to the genus Proteus and a use thereof. The inventors of the present invention experimentally confirmed that the vesicles was significantly reduced in samples of patients with cancers, allergic-respiratory diseases, cardiovascular diseases, metabolic diseases, or neuropsychiatric diseases, as compared to that of normal people, and the vesicles inhibited the secretion of inflammatory mediators due to pathogenic vesicles and also exhibited anticancer efficacy. Therefore, it is anticipated that the vesicles derived from bacteria belonging to the genus Proteus, according to the present invention, may be usefully used for the development of a method of diagnosing cancer, cardiovascular diseases, metabolic diseases, neuropsychiatric diseases, allergic-respiratory diseases, and inflammatory bowel diseases, and a composition for prevention, treatment, and/or alleviation.

Abstract: The present invention relates to, in part, compositions and methods for delivery of novel mixtures of bacterial strains for maintaining and/or restoring a healthy gut barrier.

Abstract: A selective microbial detection device and methods of use are provided. The device includes a water-proof pouch that includes a first wall portion, a second wall portion, and a porous membrane filter disposed in the pouch between the first and second wall portions. The filter membrane divides the pouch into first and second compartments. The microbial detection device also includes an effective amount of a dry nutrient disposed in the first compartment, which contains sodium lauryl sulfate in an amount of 1.75 milligrams or greater per twelve square inches of the first wall portion. A dry, cold water-soluble gelling agent is adhered to the pouch in the first compartment and an absorbent pad is disposed in the second compartment. A sealable sample port provides access to deposit a liquid into the first compartment.

Abstract: Compositions capable of enhancing and/or eliciting an immune response in a subject and methods of using the compositions. The compositions are capable of enhancing an IgA immune response and/or an IgG immune response and comprise an agent capable of reducing the level of binding of ATP to a P2X7 receptor to a subject. The compositions are for oral administration.

Abstract: The present invention discloses yeast powder rich in nicotinamide mononucleotide, a preparation method and uses thereof. The preparation method includes: preparing a first medium, a second medium, and a third medium; inoculating the first medium with yeast for fermentation to obtain a first fermentation broth; inoculating the second medium with the first fermentation broth for fermentation to obtain a second fermentation broth; inoculating the third medium with the second fermentation broth for fermentation to obtain a third fermentation broth; centrifuging the third fermentation broth to obtain a fermented product; and drying the fermented product to obtain the yeast powder. Components of the first medium, the second medium and the third medium include nicotinamide, tryptophan and niacin. The content of nicotinamide mononucleotide in the yeast powder is at least 5000 ppm.